[{"orgOrder":0,"company":"Eclipse Bioinnovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Eclipse Bioinnovations","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Bioinnovations \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Eclipse Bioinnovations \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Eclipse Bioinnovations

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : eMERGE is an end-to-end solution for the characterization and optimization of RNA-based therapeutic products, including vaccines, protein and gene therapies, and monoclonal antibodies.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 24, 2024

                          Lead Product(s) : RNA-Based Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank